ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > New info an plaque removal

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Apr 17, 2023 8:15pm

84 Views

Post# 35399537

RE:New info an plaque removal

is it just me or are these articles trying to correlate plaque removal with improved health outcomes?

Just wait til they finally catch up and learn that plaque clearance is just a side effect of these not-fully targeted drugs that are actually improving health outcomes by removing toxic oligomers of amyloid beta, not plaques

And plaque removal actually has drawbacks wrt ARIA E

And then wait til the market figures it out. to infinity and beyond PMN

<< Previous

Bullboard Posts

Next >>

Geologica Resource: Polymetallic upside at a depressed price